Corcept Therapeutics Incorporated

Healthcare · Biotechnology · United States

Last price 85.95 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 9.29B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It also develops relacorilant, a selective cortis...